137 related articles for article (PubMed ID: 34723562)
1. Decapeptide Modified Doxorubicin Loaded Solid Lipid Nanoparticles as Targeted Drug Delivery System against Prostate Cancer.
De K
Langmuir; 2021 Nov; 37(45):13194-13207. PubMed ID: 34723562
[TBL] [Abstract][Full Text] [Related]
2. Decapeptide functionalized targeted mesoporous silica nanoparticles with doxorubicin exhibit enhanced apoptotic effect in breast and prostate cancer cells.
Tambe P; Kumar P; Paknikar KM; Gajbhiye V
Int J Nanomedicine; 2018; 13():7669-7680. PubMed ID: 30538451
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin Loaded Silica Nanoparticles with Dual Modification as a Tumor-Targeted Drug Delivery System for Colon Cancer Therapy.
Lin YQ; Zhang J; Liu SJ; Ye H
J Nanosci Nanotechnol; 2018 Apr; 18(4):2330-2336. PubMed ID: 29442900
[TBL] [Abstract][Full Text] [Related]
4. Aptamer-conjugated and doxorubicin-loaded unimolecular micelles for targeted therapy of prostate cancer.
Xu W; Siddiqui IA; Nihal M; Pilla S; Rosenthal K; Mukhtar H; Gong S
Biomaterials; 2013 Jul; 34(21):5244-53. PubMed ID: 23582862
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo Evaluation of Folic Acid Modified DOX-Loaded
Deng H; Wang Y; Zhou Y; Zhai D; Chen J; Hao S; Chen X
Int J Nanomedicine; 2023; 18():2003-2015. PubMed ID: 37077940
[TBL] [Abstract][Full Text] [Related]
6. Doxorubicin-loaded amphiphilic polypeptide-based nanoparticles as an efficient drug delivery system for cancer therapy.
Lv S; Li M; Tang Z; Song W; Sun H; Liu H; Chen X
Acta Biomater; 2013 Dec; 9(12):9330-42. PubMed ID: 23958784
[TBL] [Abstract][Full Text] [Related]
7. Combination prostate cancer therapy: Prostate-specific membranes antigen targeted, pH-sensitive nanoparticles loaded with doxorubicin and tanshinone.
Sun G; Sun K; Sun J
Drug Deliv; 2021 Dec; 28(1):1132-1140. PubMed ID: 34121558
[TBL] [Abstract][Full Text] [Related]
8. Surface functionalization of doxorubicin-loaded liposomes with octa-arginine for enhanced anticancer activity.
Biswas S; Dodwadkar NS; Deshpande PP; Parab S; Torchilin VP
Eur J Pharm Biopharm; 2013 Aug; 84(3):517-25. PubMed ID: 23333899
[TBL] [Abstract][Full Text] [Related]
9. Design, development, and in-vitro/in-vivo evaluation of docetaxel-loaded PEGylated solid lipid nanoparticles in prostate cancer therapy.
Korake S; Bothiraja C; Pawar A
Eur J Pharm Biopharm; 2023 Aug; 189():15-27. PubMed ID: 37270157
[TBL] [Abstract][Full Text] [Related]
10. Biotin-Conjugated Multilayer Poly [D,L-lactide-co-glycolide]-Lecithin-Polyethylene Glycol Nanoparticles for Targeted Delivery of Doxorubicin.
Dai Y; Xing H; Song F; Yang Y; Qiu Z; Lu X; Liu Q; Ren S; Chen X; Li N
J Pharm Sci; 2016 Sep; 105(9):2949-2958. PubMed ID: 27209461
[TBL] [Abstract][Full Text] [Related]
11. The chemotherapeutic potential of doxorubicin-loaded PEG-b-PLGA nanopolymersomes in mouse breast cancer model.
Alibolandi M; Sadeghi F; Abnous K; Atyabi F; Ramezani M; Hadizadeh F
Eur J Pharm Biopharm; 2015 Aug; 94():521-31. PubMed ID: 26170161
[TBL] [Abstract][Full Text] [Related]
12. Adenosine conjugated lipidic nanoparticles for enhanced tumor targeting.
Swami R; Singh I; Jeengar MK; Naidu VG; Khan W; Sistla R
Int J Pharm; 2015; 486(1-2):287-96. PubMed ID: 25839415
[TBL] [Abstract][Full Text] [Related]
13. Novel transferrin modified and doxorubicin loaded Pluronic 85/lipid-polymeric nanoparticles for the treatment of leukemia: In vitro and in vivo therapeutic effect evaluation.
Zhu B; Zhang H; Yu L
Biomed Pharmacother; 2017 Feb; 86():547-554. PubMed ID: 28024291
[TBL] [Abstract][Full Text] [Related]
14. Targeted delivery of doxorubicin into tumor cells by nanostructured lipid carriers conjugated to anti-EGFRvIII monoclonal antibody.
Abdolahpour S; Toliyat T; Omidfar K; Modjtahedi H; Wong AJ; Rasaee MJ; Kashanian S; Paknejad M
Artif Cells Nanomed Biotechnol; 2018 Feb; 46(1):89-94. PubMed ID: 28296511
[TBL] [Abstract][Full Text] [Related]
15. LHRH-conjugated, PEGylated, poly-lactide-co-glycolide nanocapsules for targeted delivery of combinational chemotherapeutic drugs Docetaxel and Quercetin for prostate cancer.
Shitole AA; Sharma N; Giram P; Khandwekar A; Baruah M; Garnaik B; Koratkar S
Mater Sci Eng C Mater Biol Appl; 2020 Sep; 114():111035. PubMed ID: 32994029
[TBL] [Abstract][Full Text] [Related]
16. Redox and pH dual responsive poly(amidoamine) dendrimer-poly(ethylene glycol) conjugates for intracellular delivery of doxorubicin.
Hu W; Qiu L; Cheng L; Hu Q; Liu Y; Hu Z; Chen D; Cheng L
Acta Biomater; 2016 May; 36():241-53. PubMed ID: 26995505
[TBL] [Abstract][Full Text] [Related]
17. Polyethylene glycol-modified arachidyl chitosan-based nanoparticles for prolonged blood circulation of doxorubicin.
Termsarasab U; Yoon IS; Park JH; Moon HT; Cho HJ; Kim DD
Int J Pharm; 2014 Apr; 464(1-2):127-34. PubMed ID: 24451239
[TBL] [Abstract][Full Text] [Related]
18. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
Hadinoto K; Sundaresan A; Cheow WS
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180
[TBL] [Abstract][Full Text] [Related]
19. Folic acid-conjugated polyethylene glycol-coated magnetic nanoparticles for doxorubicin delivery in cancer chemotherapy: Preparation, characterization and cytotoxicity on HeLa cell line.
Erdem M; Yalcin S; Gunduz U
Hum Exp Toxicol; 2017 Aug; 36(8):833-845. PubMed ID: 27758842
[TBL] [Abstract][Full Text] [Related]
20. Lipid-polymer hybrid nanoparticles for controlled delivery of hydrophilic and lipophilic doxorubicin for breast cancer therapy.
Tahir N; Madni A; Correia A; Rehman M; Balasubramanian V; Khan MM; Santos HA
Int J Nanomedicine; 2019; 14():4961-4974. PubMed ID: 31308666
[No Abstract] [Full Text] [Related]
[Next] [New Search]
